Unknown

Dataset Information

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification.


ABSTRACT: Background: In non-small cell lung cancer (NSCLC) patients harboring MET mutations, MET-tyrosine kinase inhibitors (TKIs) have been proven to achieve a good response. However, the relative efficacy of different therapeutics in primary NSCLC patients with MET amplification and the treatment options for patients harboring acquired MET amplification after the failure of epidermal growth factor receptor (EGFR)-TKIs remain unclear. Methods: In total, 33 patients harboring primary MET amplification and 9 patients harboring acquired MET alterations identified by next-generation sequencing were enrolled. A retrospective analysis was conducted to compare the efficacy of different therapeutics. In addition, studies reporting various treatments for pat

SUBMITTER: Sun D 

PROVIDER: S-EPMC9511535 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature